|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||310.430 g/mol|
Plomestane (INN, USAN; MDL-18,962), also referred to as propargylestrenedione (PED), is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer. It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.
- F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1635. ISBN 978-0-412-46630-4. Retrieved 19 May 2012.
- Dr. Ian Morton; Ian K. M. Morton; Judith M. Hall; Dr. Judith Hall (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 227. ISBN 978-0-7514-0499-9. Retrieved 20 May 2012.
- Bentham Science Publishers (June 1995). Current Pharmaceutical Design. Bentham Science Publishers. p. 45. Retrieved 20 May 2012.
- Richard B. Kreider; Brian C. Leutholtz; Frank I. Katch; Victor L. Katch (2009). Exercise and Sport Nutrition. Exercise & Sport Nutrition. p. 350. ISBN 978-0-9742965-6-2. Retrieved 20 May 2012.
- Kelloff GJ, Lubet RA, Lieberman R, et al. (January 1998). "Aromatase inhibitors as potential cancer chemopreventives". Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 7 (1): 65–78. PMID 9456245.
- Carmen Avendaño; J. Carlos Menéndez (4 June 2008). Medicinal Chemistry of Anticancer Drugs. Elsevier. p. 69. ISBN 978-0-444-52824-7. Retrieved 20 May 2012.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|